Discontinuation of Postmenopausal Hormone Therapy: Impact on the Cardiovascular System and Quality of Life
Menopause, Atherosclerosis, Cardiovascular Diseases
About this trial
This is an interventional basic science trial for Menopause focused on measuring Randomized Controlled Trial, Menopause, Hormone Therapy, Vasomotor symptoms, Quality of Life, Cardiovascular diseases, Endothelium
Eligibility Criteria
Inclusion Criteria:
- healthy postmenopausal women
- age ≤ 60 years
- has used postmenopausal hormone therapy for at least 3 years
Exclusion Criteria:
- any clinically significant disease
- use of regular medication
- history of cardiovascular events
- history of smoking
- body mass index over 30 kg/m2
- thickness of endometrium over 6 millimeters
Sites / Locations
- HUS Women's HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Other
Other
Active Comparator
Group A, Abrupt Discontinuation
Group B, Tapered Discontinuation
Group C, Control Group
Women in group A will discontinue HT (estradiol, 2 mg daily) abruptly after study week 9 and will continue with placebo for study weeks 10-20.
Women in group B will discontinue HT (estradiol, 2 mg daily) gradually during study weeks 7-9, as follows: weeks 7-9: 1 mg estradiol daily for 10 days and then 1 mg estradiol every other day for 11 days. weeks 10-20: placebo
Women in Group C, the control group, will continue with HT (estradiol, 2 mg daily) throughout the whole study period of 20 weeks.